Under the license agreement, CSL will obtain non-exclusive rights to use Potelligent technology platform to research, develop, manufacture, and commercialize antibody-dependent cellular cytotoxicity (ADCC)-enhanced antibodies for an undisclosed
Circassia has also entered into agreements with pharmaceutical manufacturers Excella and Hospira to establish a commercial-scale supply chain for the product. Circassia is developing dopexamine in a new
Mr De Vaere’s most recent position was as senior vice president, finance and administration and CFO of IDM Pharma, a biopharmaceutical company focused on the development of innovative
The Phase I study is an open-label, single center, ascending dose trial that will determine the safety and tolerance of multiple administrations of the synthetic retinoid drug in
Ms McGarraugh has joined Apieron as vice president of marketing in January 2008. Ms McGarraugh was previously vice president of worldwide marketing for in vivo products at Abbott
The first Phase I study is a double-blind and placebo-controlled single ascending dose study in healthy male volunteers to evaluate the compound’s safety, tolerability, pharmacokinetic profile and pharmacodynamic
The approval is based on data from two Phase III, 12-week, randomized, double-blind, placebo-controlled, multi-center studies as well as a 40 week open label study. In the two
Shionogi has completed the acquisition through a cash tender offer followed by short-form merger of the indirect wholly owned subsidiary of Shionogi with and into Sciele. Sciele is
The placebo-controlled, dose-escalating trial is designed to evaluate the safety, tolerability and intraocular pressure (IOP)-lowering effects of INS117548 in approximately 60 subjects with early stage glaucoma or ocular
Toccata is a 70 patient European multi-center safety study. Constructed to gain the CE Mark for the treatment of atrial arrhythmias, secondary endpoints were designed to evaluate the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.